BioAgilytix Names Two New Scientific Officers

BioAgilytix Labs LLC, a global contract research organization focused on supporting pharmaceutical and biotech partners in all phases of drug development, has appointed two new scientific officers.
 
Lynn Kamen and Michelle Miller bring with them more than two decades of experience combined in drug discovery, development and immunology and toxicology.
 
The addition of Kamen and Miller to the Scientific Office brings the total number on that team to five.
 
Jim McNally, chief scientific officer at BioAgilytix, said, “We are delighted to welcome Lynn and Michelle to our team. They will both be valuable assets to our internal teams and partners to our clients. Their experience with drug development and bioanalytical support will immediately add value to BioAgilytix.”

Kamen is an immunologist who has extensive experience in both large and small molecule in drug development across the therapeutic areas of oncology, cancer immunotherapy, immunology, ophthalmology, and neurology. She has experience working with novel modalities, including bispecific antibodies and cell therapies and is an accomplished mentor and supervisor of both scientists and research associates.

From 2014 to 2022, Kamen worked at Genentech as a principal scientist within the Development Sciences organization leading the bioanalytical analysis for large molecules from late-stage research through the clinic.
 
Kamen, said: “I’m incredibly excited to join BioAgilytix, and look forward to drawing on my experience in drug development with the goal of collaborating and solving bioanalytical challenges on a global scale.”

Miller worked with BioAgilytix previously as a bioanalytical associate director where she collaborated closely with clients and operational staff to assure successful on-time execution of assays, validation, and sample analysis under GxP, supporting preclinical, clinical and product release studies.

Prior to joining the company, she led GLP toxicology and immunotoxicology studies and developed high throughput screening assays as a lead investigator. She also worked as an R&D scientist in the pharmaceutical industry. She is a current Diplomate of the American Board of Toxicology.
 
Miller added that she was thrilled to continue to advance her career with BioAgilytix: “In my time at BioAgilytix, I have been able to work with an amazing community of scientists, both internally and externally, to deliver ground-breaking therapeutics to the people that need them most. In this new role, I look forward to continuing those relationships and serving as an additional scientific resource wherever I can.”